INSM Valuation

Insmed Inc

Add to Watchlist

Advanced Chart

127.685

+0.415(0.326%)1D

Overview
Forecast
Valuation
Earnings

INSM Relative Valuation

INSM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INSM is overvalued; if below, it's undervalued.

Historical Valuation

Insmed Inc (INSM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 41.26 is considered Overvalued compared with the five-year average of -9.06. The fair price of Insmed Inc (INSM) is between 32.31 to 77.83 according to relative valuation methord. Compared to the current price of 129.28 USD , Insmed Inc is Overvalued By 66.11%.

Relative Value

Fair Zone

32.31-77.83

Current Price：129.28

66.11%

Overvalued

-24.05

Trailing

Forward

-31.73

EV/EBITDA

Insmed Inc. (INSM) has a current EV/EBITDA of -31.73. The 5-year average EV/EBITDA is -10.30. The thresholds are as follows: Strongly Undervalued below -20.18, Undervalued between -20.18 and -15.24, Fairly Valued between -5.36 and -15.24, Overvalued between -5.36 and -0.42, and Strongly Overvalued above -0.42. The current Forward EV/EBITDA of -31.73 falls within the Strongly Undervalued range.

-23.73

EV/EBIT

Insmed Inc. (INSM) has a current EV/EBIT of -23.73. The 5-year average EV/EBIT is -9.50. The thresholds are as follows: Strongly Undervalued below -18.31, Undervalued between -18.31 and -13.90, Fairly Valued between -5.09 and -13.90, Overvalued between -5.09 and -0.69, and Strongly Overvalued above -0.69. The current Forward EV/EBIT of -23.73 falls within the Strongly Undervalued range.

41.26

Insmed Inc. (INSM) has a current PS of 41.26. The 5-year average PS is 16.80. The thresholds are as follows: Strongly Undervalued below -1.37, Undervalued between -1.37 and 7.71, Fairly Valued between 25.88 and 7.71, Overvalued between 25.88 and 34.96, and Strongly Overvalued above 34.96. The current Forward PS of 41.26 falls within the Strongly Overvalued range.

-31.24

P/OCF

Insmed Inc. (INSM) has a current P/OCF of -31.24. The 5-year average P/OCF is -10.70. The thresholds are as follows: Strongly Undervalued below -20.88, Undervalued between -20.88 and -15.79, Fairly Valued between -5.62 and -15.79, Overvalued between -5.62 and -0.53, and Strongly Overvalued above -0.53. The current Forward P/OCF of -31.24 falls within the Strongly Undervalued range.

-31.62

P/FCF

Insmed Inc. (INSM) has a current P/FCF of -31.62. The 5-year average P/FCF is -9.89. The thresholds are as follows: Strongly Undervalued below -20.10, Undervalued between -20.10 and -14.99, Fairly Valued between -4.78 and -14.99, Overvalued between -4.78 and 0.32, and Strongly Overvalued above 0.32. The current Forward P/FCF of -31.62 falls within the Strongly Undervalued range.

Insmed Inc (INSM) has a current Price-to-Book (P/B) ratio of 21.59. Compared to its 3-year average P/B ratio of 41.52 , the current P/B ratio is approximately -48.00% higher. Relative to its 5-year average P/B ratio of 30.78, the current P/B ratio is about -29.86% higher. Insmed Inc (INSM) has a Forward Free Cash Flow (FCF) yield of approximately -3.22%. Compared to its 3-year average FCF yield of -11.01%, the current FCF yield is approximately -70.80% lower. Relative to its 5-year average FCF yield of -10.63% , the current FCF yield is about -69.76% lower.

21.59

P/B

Median3y

41.52

Median5y

30.78

-3.22

FCF Yield

Median3y

-11.01

Median5y

-10.63

Competitors Valuation Multiple

The average P/S ratio for INSM's competitors is 21.18, providing a benchmark for relative valuation. Insmed Inc Corp (INSM) exhibits a P/S ratio of 41.26, which is 94.79% above the industry average. Given its robust revenue growth of 18.90%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Ascentage Pharma Group International

Performance Decomposition

Market capitalization of INSM increased by 66.43% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -14.18 to -22.34.

The secondary factor is the Revenue Growth, contributed 18.90%to the performance.

Overall, the performance of INSM in the past 1 year is driven by P/E Change. Which is more unsustainable.

18.90%

90.34M → 107.42M

Revenue Growth

-10.00%

-332.75 → -299.48

Margin Expansion

57.53%

-14.18 → -22.34

P/E Change

66.43%